A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

18.1K views

⸱

DOI:

10.3791/1955

⸱

May 13th, 2010

 , 

In This Article

Summary

Aptamers are short ribo-/deoxyribo-oligonucleotides selected by in-vitro evolution methods based on affinity for a specific target. Aptamers are molecular recognition tools with versatile therapeutic, diagnostic, and research applications. We demonstrate methods for selection of aptamers for amyloid β-protein, the causative agent of Alzheimer's disease.

Abstract

Alzheimer's disease (AD) is a progressive, age-dependent, neurodegenerative disorder with an insidious course that renders its presymptomatic diagnosis difficult1. Definite AD diagnosis is achieved only postmortem, thus establishing presymptomatic, early diagnosis of AD is crucial for developing and administering effective therapies2,3.

Amyloid β-protein (Aβ) is central to AD pathogenesis. Soluble, oligomeric Aβ assemblies are believed to affect neurotoxicity underlying synaptic dysfunction and neuron loss in AD4,5. Various forms of soluble Aβ assemblies have been described, however, their interrelationships and relevance to AD etiology and pathogenesis are complex and not well understood6. Specific molecular recognition tools may unravel the relationships amongst Aβ assemblies and facilitate detection and characterization of these assemblies early in the disease course before symptoms emerge. Molecular recognition commonly relies on antibodies. However, an alternative class of molecular recognition tools, aptamers, offers important advantages relative to antibodies7,8. Aptamers are oligonucleotides generated by in-vitro selection: systematic evolution of ligands by exponential enrichment (SELEX)9,10. SELEX is an iterative process that, similar to Darwinian evolution, allows selection, amplification, enrichment, and perpetuation of a property, e.g., avid, specific, ligand binding (aptamers) or catalytic activity (ribozymes and DNAzymes).

Despite emergence of aptamers as tools in modern biotechnology and medicine11, they have been underutilized in the amyloid field. Few RNA or ssDNA aptamers have been selected against various forms of prion proteins (PrP)12-16. An RNA aptamer generated against recombinant bovine PrP was shown to recognize bovine PrP-β17, a soluble, oligomeric, β-sheet-rich conformational variant of full-length PrP that forms amyloid fibrils18. Aptamers generated using monomeric and several forms of fibrillar β2-microglobulin (β2m) were found to bind fibrils of certain other amyloidogenic proteins besides β2m fibrils19. Ylera et al. described RNA aptamers selected against immobilized monomeric Aβ4020. Unexpectedly, these aptamers bound fibrillar Aβ40. Altogether, these data raise several important questions. Why did aptamers selected against monomeric proteins recognize their polymeric forms? Could aptamers against monomeric and/or oligomeric forms of amyloidogenic proteins be obtained? To address these questions, we attempted to select aptamers for covalently-stabilized oligomeric Aβ4021 generated using photo-induced cross-linking of unmodified proteins (PICUP)22,23. Similar to previous findings17,19,20, these aptamers reacted with fibrils of Aβ and several other amyloidogenic proteins likely recognizing a potentially common amyloid structural aptatope21. Here, we present the SELEX methodology used in production of these aptamers21.

Protocol

Part 1: Protein preparation and cross-linking

Initially, the protein used for SELEX is pretreated with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to obtain homogeneous, aggregate-free preparations, as described previously23. This step is necessary because pre-formed aggregates induce rapid aggregation of amyloidogenic proteins, resulting in poor experimental reproducibility24, and are undesirable for selection of aptamers for unaggregated, non-fibrillar forms of the protein.

  1. Weigh out ~800 μg (~180 nmol) pure Aβ40 using a microbalance. Transfer the dry lyophilized peptide into labeled, silicon-coated, low-....

Access restricted. Please log in or start a trial to view this content.

Discussion

The starting point of the SELEX process is synthesis of a random oligonucleotide library typically containing 1012-1015 sequences. In DNA SELEX, this library is used directly after a ssDNA pool is generated, whereas in RNA SELEX, demonstrated here, the ssDNA library is converted first to an RNA pool enzymatically by in-vitro transcription. Then, SELEX is performed iteratively whereby each cycle comprises exposure and binding of oligonucleotides to the intended target, partitioning of binder.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

No conflicts of interest declared.

Acknowledgements

This work was supported by grants AG030709 from NIH/NIA and 07-65798 from the California Department of Public Health. We acknowledge Margaret M. Condron for peptide synthesis and amino acid analysis, Dr. Elizabeth F. Neufeld for helping and supporting the initial steps of the project, Dr. Chi-Hong B. Chen for providing support and reagents, and Dr. Andrew D. Ellington for helpful discussions.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Aβ40UCLA Biopolymers LaboratoryLyophilized powder
MX5 Automated-S MicrobalanceMettler Toledo
Silicon-coated, 1.6-ml tubesDenville ScientificC19033 or C19035
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP)TCI AmericaH0424Use in a fume hood.
Ammonium persulfateSigma-AldrichA-7460Vortex until the solution is clear. APS is prepared freshly each time and should be used within 48 h.
Tris(2,2-bipridyl)dichlororuthenium(II) hexahydrateSigma-Aldrich224758-1GVortex until the solution is clear. Cover the RuBpy tube with foil to protect the reagent from ambient light. RuBpy is prepared freshly each time and should be used within 48 h.
Dithiothreitol (DTT)Sigma-Aldrich43815
D-Salt™ Excellulose™ desalting columnsThermo Fisher Scientific, Inc.20449
Ammonium acetateFisher ScientificA637-500
Silicon-coated, 0.6-ml tubesDenville ScientificC19063
Novex Tricine Gels (10–20%)InvitrogenEC6625B0X10-well; mini size (8 cm X 8 cm); 25 μl loading volume per well; separation range 5 kDa to 40 kDa
Quartz cuvetteHellma105.250-QS
Beckman DU 640 spectrophotometerBeckman Coulter Inc.
ssDNA libraryIntegrated DNA TechnologiesCustom-orderedThe library was designed to contain 49 random nucleotides flanked by two constant regions containing primer-binding and cloning sites: 5’-TAA TAC GAC TCA CTA TAG GGA ATT CCG CGT GTG C (N:25:25:25:25%) (N)49 G TCC GTT CGG GAT CCT C-3’
Taq DNA polymeraseUSB Corp., Affymetrix71160Recombinant Thermus aquaticus DNA Polymerase supplied with 10× PCR Buffer and a separate tube of 25 mM MgCl2 for routine PCR.
PCR Nucleotide Mix, 10 mM solutionUSB Corp., Affymetrix77212(10 mM each dATP, dCTP, dGTP, dTTP)
Forward primerIntegrated DNA TechnologiesCustom-ordered5’-TAA TAC GAC TCA CTA TAG GGA ATT CCG CGT GTG C-3’
Reverse primerIntegrated DNA TechnologiesCustom-ordered5’-GAG GAT CCC GAA CGG AC-3’
Thermal cyclerDenville ScientificTechne TC-312
QIAquick PCR Purification Kit (50)Qiagen28104
AgaroseDenville ScientificCA3510-8
Conical, sterile 1.6-ml tubes with caps attached with O-ringsDenville ScientificC19040-S
RiboMAX™ Large Scale RNA Production System–T7Promega Corp.P1300The kit contains: 120 μl Enzyme Mix (RNA polymerase, recombinant RNasin® ribonuclease inhibitor and recombinant inorganic pyrophosphatase); 240 μl transcription 5 buffer; 100 μl each of 4 rNTPs, 100 mM; 110 U RQ1 RNase-free DNase, 1 U/μl; 10 μl linear control DNA, 1 mg/ml; 1 ml 3M sodium acetate (pH 5.2); 1.25 ml nuclease-Free water
α-32P-cytidine 5’-triphosphate, 250 μCi (9.25 MBq), PerkinElmer, Inc.BLU008H250UCSpecific Activity: 3000 Ci (111 TBq)/mmol, 50 mM Tricine (pH 7.6)
Citrate-saturated phenol:chloroform:isoamyl alcohol (125:24:1, pH 4.7)Sigma-Aldrich77619
Chloroform:Isoamyl alcohol (24:1)Sigma-AldrichC0549
Absolute ethanol for molecular biologySigma-AldrichE7023
Z216-MK refrigerated microcentrifugeDenville ScientificC0216-MK
illustra ProbeQuant™ G-50 Micro ColumnsGE HealthcareObtained from Fisher Scientific (45-001-487)Prepacked with Sephadex™ G-50 DNA Grade and pre-equilibrated in STE buffer containing 0.15% Kathon as Biocide
Triathler Bench-top Scintillation counterHidex Oy, Turku, FinlandTriathler LSC Model: 425-034
Novex® TBE-Urea Sample Buffer (2×)InvitrogenLC6876
6% TBE-Urea Gels 1.0 mm, 10 wellsInvitrogenEC6865BOX
Novex® TBE Running Buffer (5×)InvitrogenLC6675
Radioactivity decontaminantFisher Scientific04-355-67
Gel-loading tipsDenville ScientificP3080
XCell SureLock Mini-CellInvitrogenEI0001XCell SureLock Mini-Cell
Autoradiography filmDenville ScientificE3018Use in complete darkness
Autoradiography film, Hyperfilm™ ECLAmershamRPN3114KCan be used under red safe light.
Membrane discsEMD MilliporeGSWP02500Mixed cellulose ester, hydrophilic, 0.22-μm disc membranes
Fritted glass support base for 125-ml flaskVWR international26316-696
Petri dishesFisher Scientific08-757-11YZ
UreaFisher ScientificAC32738-0050
EDTAFisher Scientific118430010
GlycogenSigma-AldrichG1767
2-Propanol for molecular biologySigma-AldrichI9516
Recombinant RNase inhibitorUSB Corp., Affymetrix71571
ImProm-II™Reverse Transcription SystemPromega Corp.A3802
Recombinant RNase inhibitorUSB Corp., Affymetrix71571
RapidRun™ Loading DyeUSB Corp., Affymetrix77524

References

  1. Monien, B. H., Apostolova, L. G., Bitan, G. Early diagnostics and therapeutics for Alzheimer's disease-how early can we get there. Expert. Rev. Neurother. 6, 1293-1306 (2006).
  2. Nestor, P. J., Scheltens, P., Hodges, J. R. Advances in the early detection of Alzheimer's d....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Aptamer SelectionSELEX MethodologyAmyloid Beta 40RNA BindingFilter Binding AssayIn Vitro TranscriptionProtein Cross-linkingPICUP ProcedureGel ElectrophoresisScintillation Counting